<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval
Image Overlay - First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

December 10, 2020

First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer Receives Approval

The U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) – the first drug for to be used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. Yourway is dedicated to supporting clinical trials for innovative and badly needed drugs like this.

 Back to Index
Media

Upcoming Events

Clinical Trial Supply East Coast 2022

October 19-20, 2022
King of Prussia, PA, USA

Media

Articles

Helping Sponsors Navigate Complex Ancillary Supply Sourcing Challenges with Integrated Services

Open chat
Come chat with us!
Hello! How can I help you?